header logo image


Page 190«..1020..189190191192..200210..»

The Final Verdict On Which Vitamins Actually Boost Your Immunity Eat This Not That – Eat This, Not That

November 7th, 2021 1:55 am

When cold and flu season comes around, tissues aren't the only thing we stock up on. Many of us rely on immune-boosting supplements that we either take throughout the season or whenever we feel a cold coming on to help lessen symptoms. While taking supplements isn't necessary if you have a well-balanced diet rich in whole foods and immune-supporting nutrients, it's always helpful to have the option of getting some virus-fighting reinforcements from vitamin supplements.

But have you walked down the supplement aisle recently? If so, you probably already know that there's no shortage of supplements that claim to support your immune health; however, what you may not realize is that there are only a few that are scientifically proven to do what they claim. We spoke to Mia Syn, MS, RDN, a South Carolina-based registered dietitian of Nutrition by Mia to identify which vitamins actually boost your immunity. Read on, and for more on how to eat healthy, don't miss 7 Healthiest Foods to Eat Right Now.

The sunshine vitamin plays a key role in brightening up your immune system."In addition to its critical role in calcium and bone homeostasis, vitamin D plays a key role in modulating the immune response," says Syn. Just how much of a role does vitamin D play in your immune response? "Vitamin D receptors are expressed on immune cells!" explains Syn, who adds that "deficiency in vitamin D is associated with increased susceptibility to infection."

What to buy: For the most effective immune-boosting vitamin D supplement, you're going to want to look for calcifediol: an active form of vitamin D. A calcifediol supplement does not need to be processed by the liver like a vitamin D2 or D3 supplement would (these are the more common types of vitamin D you'll see sold), so it can be absorbed directly into the bloodstream. This makes a calcifediol supplementthree times more effective in raising vitamin D levels when compared to vitamin D3.

RELATED: Sign up for our newsletter to get daily recipes and food news in your inbox!

Vitamin K2 is a fat-soluble vitamin that is most commonly associated with blood coagulation; however, that's not the only role it plays in the human body. This vitamin also modulates the immune response. "While vitamin D is vital for immune health, it is important to note that vitamin D supplementation is critically important in relation to vitamin K2. Vitamin K2's main role is to work with vitamin D to regulate the transport and distribution of calcium in the body to support heart and bone health. Without enough vitamin K2, osteocalcin remains inactive and calcium will not be integrated into our skeletal system which can lead to excess calcium that can be deposited in the cardiovascular system, where it can have harmful effects," says Syn.

What to buy: There are two different types of vitamin K, and it's important to understand that we're talking about vitamin K2, not K1. Vitamin K is a cofactor for anti-inflammatory proteins and vitamin K2 is more active than K1.

You guessed it! Everyone's favorite immune-boosting vitamin is on our list: "Vitamin C plays a critical role in supporting various cellular functions of both the innate and adaptive immune system. This includes supporting epithelial barrier function against potential invaders and accumulating on immune cells such as neutrophils to enhance microbial killing. Additionally, it may help shorten the duration of a common cold," says Syn.

What to buy: When you're looking for the best way to support your immune system with vitamin C, you're going to want to look for "liposomal vitamin C." Liposomal vitamin C is a form of vitamin C encapsulated in liposomes, which are essentially capsules that protect the vitamin C from digestive acids and enzymes that might break it down within the digestive tract. This makes liposomal vitamin C more bioavailable than your standard vitamin C from supplements.

READ MORE:The #1 Vitamin C Supplement to Take, Says Dietitian

It's time to load up on oysters! (Oh, that's because they're naturally rich in zincnot because it's happy hour.) "Zinc is needed to develop and activate immune cells and a deficiency is characterized by impaired immune function," says Syn.

What to buy: Look for zinc lozenges, not zinc supplements in pill form. The National Institutes of Health reports that zinc lozenges may help reduce symptoms of the common cold if taken with 23 hours of the start of symptoms, but more research is needed to determine the most effective dose.

Read this next:

More:
The Final Verdict On Which Vitamins Actually Boost Your Immunity Eat This Not That - Eat This, Not That

Read More...

Vaccinated individuals infected with Covid-19 showed immune response boost: S’pore study – The Straits Times

November 7th, 2021 1:55 am

SINGAPORE - Individuals vaccinated against Covid-19 but who still caught the virus showed an "excellent boost" intheir immune response, a study by local researchers has found.

The findings are based on researchers checking the antibody levels of 150 people from Singapore who had breakthrough infections.

Dr Barnaby Young of the National Centre for Infectious Diseases (NCID) told The Straits Times the individuals' immune memory had kicked in within a few days of being infected.

This meant they showed a strong immune response to the virus, said Dr Young, head of the Singapore Infectious Diseases Clinical Research Network at NCID.

All 150, who were recruited in May this year, had mild Covid-19 disease.

The study, which is ongoing, is being conducted by NCID, the Agency for Science, Technology and Research's Infectious Diseases Labs, and Duke-NUS Medical School.

Further studies will be conducted to look at their T-cell response as well, he added.

The immune response is shaped by both the level of neutralising antibodies, which bind with the virus and prevent it from infecting one's cells, and T-cells, which helps to clear infected cells.

Dr Young explained that having immune memory means the immune system is able to recall the antigens, which are molecules on the surfaces of virus, that it was previously exposed to.

With immune memory, the body might rapidly produce antibodies to stimulate a stronger immune response when the same virus or pathogen is encountered again.

"While the neutralising antibodies may bind to the wild-typevirus, the immune boost can help to neutralise the Delta variant, as the two are not drastically different," said Dr Young, who led the study.

Some of the findings have been published in a pre-print report, which has yet to be peer-reviewed.

"We expect the antibodies to help protect against infection for current circulating variantsand probably future unknown ones, too, though this would depend on how dramatically it changes from Delta," he added.

People waiting at the Covid-19 vaccination centre at Tanjong Pagar Community Club on Oct 12, 2021. ST PHOTO: JASON QUAH

Further studies will be needed to determine how quickly these antibodies will wane later on, and whether the level of antibodies will be strong enough to protect against future reinfections, said Dr Young.

The immune boost does not necessarily mean breakthrough infections will not occur again.

Professor Paul Tambyah, president of the Asia Pacific Society of Clinical Microbiology and Infection, said having high antibody levels may not always correlate with greater protection against infection.

"In fact, many individuals who were doubly vaccinated had high titres of antibodies yet developed symptomatic Covid-19 infection. The immune response is actually a lot more than just antibody levels," he added.

A titre is a measure of concentration.

Aside from the T-cell response, the immune response also comprises the innate immune response, which is the body's first line of defence against all antigens.

Antibodies can protect against most infections, such as hepatitis B and measles.

But "not so good" antibodies, which may be produced following vaccinations against the respiratory syncytial virus and possibly dengue, could lead to severe infections, he noted.

As for Covid-19, it is unclear whether those who had breakthrough infections would be protected against reinfection, given that current vaccines do not protect against infection very well, said Prof Tambyah.

In the best-case scenario, with a high vaccination rate and as more of the population is infected with Covid-19, the risk of severe disease will be low, said Prof Tambyah.

A previous Duke-NUS study done with NCID on survivors of the severe acute respiratory syndrome, or Sars,showed that they had a powerful antibody boost against a range of beta-coronaviruses when they were given a single dose of Covid-19 vaccine.

Natural infection and vaccination may provide long-lasting immunity, noted Prof Tambyah.

He added that some scientists believe Covid-19 booster jabs will be needed to protect against reinfection, like with hepatitis B, which requires three jabs.

Associate Professor Hsu Li Yang said certain vaccines require two or more doses to repeatedly trigger immunological memory through rapid production of antibodies -for instance, tetanus shots and the hepatitis B vaccine, as well as the vaccines protecting against Covid-19.

Even for single-dose inactivated vaccines, such as those for influenza, a second dose (or infection) will also boost antibody levels, noted Prof Hsu, who is vice-dean of global healthand infectious diseases programme leader at the National University of Singapore's Saw Swee Hock School of Public Health.

"Infection following shortly after vaccination, or vice versa, serves as an antigen challenge to the immune system, triggering a stronger response than if there were no prior exposure to the vaccine or infection," he said.

Read more from the original source:
Vaccinated individuals infected with Covid-19 showed immune response boost: S'pore study - The Straits Times

Read More...

Immune response of neonates born to mothers infected with SARS-CoV-2 – EurekAlert

November 7th, 2021 1:55 am

What The Study Did: This study of 21 mothers investigated the association of maternal SARS-CoV-2 infection with immune response in children in the first two months of life.

Authors: Rita Carsetti, M.D., of Bambino Gesu Children's Hospital in Rome, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2021.32563)

Editors Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text articleThis link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.32563?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110321

About JAMA Network Open:JAMA Network Open is thenew online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

JAMA Network Open

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more:
Immune response of neonates born to mothers infected with SARS-CoV-2 - EurekAlert

Read More...

NSCLC and COVID-19: Risks and precautions – Medical News Today

November 7th, 2021 1:55 am

People with non-small cell lung cancer (NSCLC) may have an increased risk of severe illness from COVID-19. Guidelines advise people with NSCLC to follow the same protocols as others to protect themselves from the virus while maintaining their treatment schedule and getting the vaccine when their doctor advises.

If a person with NSCLC gets a SARS-CoV-2 infection, they may be at higher risk of severe complications. Additionally, the effects of the pandemic may mean that there are delays to cancer treatment and screening. Health experts advise those with lung cancer to reduce their risk of infection and potential complications by following prevention methods, such as hand washing, mask wearing, physical distancing, and receiving the vaccine when possible.

Evidence suggests that the COVID-19 vaccines are safe and effective for individuals with NSCLC and that these shots can help lower their health risks. This is also true for people currently receiving cancer treatments, such as immunotherapy and chemotherapy. However, these individuals may require close monitoring to identify potential side effects. It is also advisable to consult a doctor regarding a suitable vaccine schedule.

This article discusses the associations between NSCLC and COVID-19, as well as the potential risks and appropriate precautions.

According to the American Cancer Society, lung cancer is among the most common forms of cancer in the United States and the leading cause of cancer deaths. There are two main types of lung cancer: NSCLC and small cell lung cancer. Approximately 84% of lung cancer cases are NSCLC, which can be difficult to treat, as it is often less sensitive to the current treatment options than other cancers.

People with NSCLC can experience symptoms that include:

People with NSCLC are also vulnerable to infection. This is because the combination of the disease and its treatments, such as chemotherapy, leads to a weakened immune system. People with cancer have a higher risk of severe illness from COVID-19.

COVID-19 is a respiratory disease that also affects the airways and lungs. The condition can cause symptoms similar to those of NSCLC, such as a persistent cough, tiredness, and breathing difficulties. Other symptoms of COVID-19 may include:

According to the Centers for Disease Control and Prevention (CDC), people with some chronic medical conditions, including cancer, are more likely than other people to develop a severe illness from COVID-19. Severe illness from COVID-19 can result in:

The increased risk for people with NSCLC can be due to the cancer itself, the cancer treatment, or a combination of both. People with NSCLC are also more likely to have other risk factors for severe illness from COVID-19, such as smoking and older age.

A 2021 review highlights evidence indicating that people with lung cancers are more likely than people with other cancers to die from COVID-19. A history of smoking and the increased pressure that the pandemic has placed on respiratory services in hospitals could contribute toward this increased risk.

Lung cancer can also cause various other complications, including blood clots, heart problems, and neuropathy.

There are many possible treatment options for people with NSCLC. These include:

The best type of treatment will depend on several factors, including the spread of the cancer and the presence of other medical conditions. Treatment will typically involve a combination of approaches.

COVID-19 has caused major disruptions to cancer care worldwide. A 2021 study suggests that the increased pressure on services during the pandemic is the main cause of these disruptions.

The treatment for NSCLC commonly involves visiting a clinic or hospital. This approach may put people with NSCLC at a higher risk of developing COVID-19 and potentially severe complications. The treatments themselves also pose additional risks by affecting the immune system. For example, chemotherapy suppresses the immune system, which reduces the bodys natural defenses against infections and disease.

People with NSCLC should discuss the risks and benefits of different treatment approaches in the context of COVID-19. In some cases, a doctor may suggest delaying treatment to minimize the risk of complications. They may also suggest that people receive a COVID-19 vaccine before initiating cancer treatments, as this may improve the chances of an adequate immune response.

COVID-19 vaccinations are a safe and effective way of preventing severe disease and limiting the spread of the virus that causes it. The CDC states that COVID-19 vaccines have been subject to the most intense safety monitoring in U.S. history.

Health experts recommend that people with most underlying medical conditions, including cancer, get the vaccine. The risks of COVID-19 are far greater for people with cancer than the risk of rare side effects from the vaccine.

However, it is important for people with cancer to discuss with a doctor when is the right time to receive the vaccination. Some cancer treatments suppress the immune system and may reduce the effectiveness of the vaccine. People who have recently received cancer treatment may benefit from waiting until their immune system fully recovers before getting the vaccine.

People with NSCLC should take additional care to avoid getting COVID-19 due to the increased risk of severe disease. The National Cancer Institute recommends that people with cancer, or a history of cancer, keep safe and minimize the risk of getting a SARS-CoV-2 infection by:

NSCLC is a serious condition that requires treatment from a doctor. Early detection is vital to catching the cancer before it spreads and to improving treatment outcomes. Anyone who experiences any symptoms of NSCLC should contact a doctor immediately.

People living with NSCLC should also contact a doctor if they notice potential symptoms of COVID-19. A doctor can advise on testing and whether to visit a clinic in person or organize a home visit.

NSCLC is a common form of lung cancer that can be fatal. As both the condition itself and its treatments can affect the immune system and lungs, lung cancer puts a person at increased risk of potentially severe complications of COVID-19. It is advisable for people with NSCLC to follow guidelines on avoiding the virus, which include receiving the vaccine.

Evidence suggests that the vaccine is safe for people with NSCLC and that it can help provide adequate protection against SARS-CoV-2. A doctor can advise when to schedule a vaccine, which may be best before or after cancer treatments, so that it provides the optimal immune response.

Original post:
NSCLC and COVID-19: Risks and precautions - Medical News Today

Read More...

Healthy Living: Autoimmunity the confused immune system – Limerick Leader

November 7th, 2021 1:55 am

I hate to be the voice of doom, but on top of the pandemic we are also facing an epidemic of allergic, asthmatic, and autoimmune disorders. You might be familiar with the first two, but when it comes to autoimmunity, most people only hear about it when they receive a diagnosis. It is certainly becoming one of the most common health concerns clients come to my clinic.

Autoimmune diseases include rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, celiac disease, Hashimoto's thyroiditis, and the many other hard-to-classify syndromes of the 21st century. At their root they are connected by one central biochemical process, an immune imbalance. Your immune system gets confused and your own tissues get caught in a crossfire. Your body is fighting something - an infection, a toxin, an allergen even food, and somehow it redirects its hostile attack on your own tissues. This immune confusion results from what is referred to as molecular mimicry: when the invader's structure is very similar to the structure of our own tissue. Interestingly, autoimmune disorders occur almost exclusively in developed countries. People in poor nations without modern amenities like running water, flush toilets, washing machines, and manicured backyards don't get these diseases. If you grew up on a farm with lots of animals, you are also less likely to have any of these inflammatory disorders. Playing in the dirt and being exposed to bugs and infections trains your immune system to recognize what is foe and what is "you." Stress has a huge impact on your immunity, weakening your ability to fight infections and increasing your chances to develop allergies and autoimmunity.Autoimmune diseases when taken all together are a huge health burden. Unfortunately, many of the conventional treatments available can make you feel worse. When used selectively, these drugs can help people get their lives back. But they are not a long-term solution. Anti-inflammatory drugs and immune suppressants may lead to multiple side effects. They shouldn't be the end of treatment, but a bridge to cool off inflammation while the root cause of the disease is found and addressed.Naturopathy sees you as a whole, not as a machinery with separate parts. No matter what part of your body is under attack by your immune system, the solution is one and the very same: you need to find the root cause and balance your immune system using a functional medicine approach, a new way of thinking about the underlying causes and imbalances in chronic disease.You are also a unique individual a mixture of your genetic makeup, your history and your environment, therefore the only real solution is finding and addressing your specific cause, ridding your body and your environment of anything that may drive your condition, healing your damaged tissues by supplying your body with immune-balancing nutrients and powerful botanicals. The journey is long, it is not easy, but it leads to quality of life without side effects and halts the spread of autoimmunity to new tissues.

See the rest here:
Healthy Living: Autoimmunity the confused immune system - Limerick Leader

Read More...

Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology – Yahoo…

November 7th, 2021 1:55 am

Data Presented at ASH Underscores the Potential of the Smart-Immune Platform That Can Generate ex-vivo T- cell progenitors and NK- Cells for the Treatment of Primary Immunodeficiencies, and Cancers

PARIS, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T-cell medicine company utilizing its proprietary ex-vivo biomimetic thymus in a dish technology to develop allogeneic T-cell progenitors Smart-101 (ProTcell) for rapid immune reconstitution, announced today the presentation of clinical data and preclinical research at the 63rd annual meeting of the American Society of Hematology (ASH), taking place December 11-14 in Atlanta, Georgia. Preliminary data in these abstracts became available on the ASH conference website 9:00 AM ET yesterday. Recently, Smart-Immune has also announced the commencement of its first US clinical trial using its T-cell progenitor product (Smart-101) for the treatment of patients with AML and ALL who receive allogeneic hematopoietic stem cell transplant (allo-HSCT).

For a young company like ours, the selection of abstracts at a prestigious hematology conference like ASH is a recognition of the potential of our platform technology to uniquely and selectively generate large numbers of T- and/or NK-progenitors with the purity and reproducibility necessary for clinical use, commented Karine Rossignol, the Chief Executive Officer and co-founder of Smart-Immune. These abstracts selected represent a decade of research by my co-founders Drs. Marina Cavazzana and Isabelle Andre to create a short and elegantly simple 7-day culture system to generate lymphoid progenitors allowing a fast (within 100 days instead of 1-2 years) a polyclonal reconstitution of a fully functional immune system able to fight cancers and infections, changing drastically the prognosis of patients. With widespread applicability across primary immunodeficiencies, and hematological cancers, and three clinical trials launched, Smart-Immune is the first company to bring allogenic human progenitor cells into clinical development.

Story continues

Abstracts accepted at ASH include:

1)

Rapid and Safe T Cell Immune Reconstitution By T Cell Progenitor Injection Following Haploidentical Transplantation for Severe Combined Immunodeficiency (SCID).

Presenter: Despina Moshous, Hospital Necker Enfants Malades

Session Name: 704. Cellular Immunotherapies: Clinical: Poster I

Session Date: Dec 11th, 2021

Session Time: 5:30 PM - 7:30 PM

Room: Georgia World Congress Center, Hall B5

Abstract Synopsis: Severe Combined Immunodeficiency (SCID), is a severe form of primary immunodeficiency, responsible for the death, within the first few months of life, if not treated with HSCT. In the absence of an HLA-identical HSC donor, an urgent haploidentical HSCT is proposed to newborns with Severe Combined Immunodeficiency (SCID). The authors describe how the Delta-4 ligand based, culture system, that is at the core of the Companys invention, can be used to generate the earliest CD7+ T-cell progenitors (Smart-101) from such a haploidentical donor. Patient outcomes for two SCID babies being treated in the ongoing Smart-Immune phase 1/2 trial in SCID, who receive Smart-101 after allogeneic HSCT is discussed. Available data indicate that when Smart-101 is used at the optimal window of time in the early weeks after birth, rapid immune reconstitution with CD3+, CD4+, CD8+ and CD19+ T-cells may result in freedom from infections and GvHD and can be lifesaving for such SCID babies. These preliminary results deserve further investigation, which will be performed as part of our ongoing clinical study.

2)

Ex Vivo Production Of Large Numbers Of Genetically Modified NK Cells From Cord Blood Or Mobilized Peripheral Blood CD34+ Cells Using Notch Ligand Delta-Like 4 Culture System

Presenter: Ranjita Devi Moirangthem, Smart-Immune SAS

Session Name: 703. Cellular Immunotherapies: Basic and Translational: Poster II

Session Date: Dec 12th, 2021

Session Time: 6:00 PM - 8:00 PM

Room: Georgia World Congress Center, Hall B5

Abstract Synopsis: In this research the authors extend the utility of the Companys proprietary Delta-4 ligand based, feeder free, culture platform from generating not just pure allogeneic T-cell CD7+ progenitors (Smart-101), but also being able to generate T-cell free, CD56+ NK-cells (Smart-103) when culture conditions are modified to be NK-conducive. Expansion of these NK-progenitors result in NK populations with normal surface markers, gene expression patterns and cytotoxicity seen in NK cells immunoselected from human beings. Allogeneic NK-therapy is at its infancy but provides many advantages over T-cell therapy in it being free from graft-versus-host disease and downstream cytokine storm in the recipient. Moreover, the Companys NK-cells are also easily gene modifiable such that the transgene is robustly expressed in the NK population, paving the way for possible future CAR- NK development expanding our technology to both lymphoid populations, i.e., T and NK cells.

At Smart-Immune, we are first and foremost focused on validating that our first cell-therapy product, which is our early progenitor T-cells (Smart-101) devoid of any form of genetic engineering, is of easy access and safe to patients in both the short-term and long-term, said Dr. Marina Cavazzana, co-founder and Chief Medical Officer of Smart-Immune. Smart-101 has to be safe and effective in what it is intended to do i.e., shorten the lymphoid immunodeficient period from 18 months to 3-6 months, benefiting infection, graft versus host (GvHD) and relapse rates, and possibly augmenting survival. Proving this in 2022-2023 will pave the way for our next phase of clinical programs starting early 2024 using CAR-ProTcell where our progenitor T-cells could bear efficient transgenes to fight cancers.

A description of all three US and European clinical trials using Smart-Immunes progenitor populations can be found on the Companys website: Smart-Immune.com

To learn more about the US clinical trial for Smart-101 in pediatric and adult leukemia, please refer to: ClinicalTrials.gov (Trial Identifier: NCT04959903)

About Smart Immune:Smart Immunes mission is to make T-cell therapy accessible and affordable to all patients and, through its groundbreaking ProTcell platform, has developed clinical stage T-cell progenitors designed to improve prognosis for patients affected by malignant blood diseases or rare primary immunodeficiencies. The company is utilizing its unique ex-vivo biomimetic thymus in a dish technology to culture specific T-cell progenitor subpopulations at clinical scale and use them for cell or gene therapy. The company was founded in 2017 by Dr Isabelle Andr, Karine Rossignol, and Dr Marina Cavazzana from Hpital Necker-Enfants Malades AP-HP, a pediatric hematologist and a pioneer in vector-based therapies and hematopoietic stem cell treatments.

About ProTcell:The Smart Immune ProTcell platform generates allogenic T-cell progenitors that provide fully functional polyclonal T-cells within 3 months following an allogeneic HSCT while also reducing GvHD, infections and relapses thereby reducing morbidity and mortality and improving the benefice risk ratio for allogeneic medicine. When infused, ProTcell progenitors migrate to the patients thymus where they expand, are selected, and then differentiate, resulting in fully functional T-cells, tolerant to the patients own immune system and reactive to viral, fungal, and malignant antigens. ProTcell has been accepted by the FDA as an Investigational New Drug (IND) for Acute Lymphocytic Leukemia (ALL) and Acute Myelocytic Leukemia (AML) and has also been granted fast track designation under its expedited program for serious conditions like SCID. In 2021, the FDA granted orphan drug designation for ProTcell as a treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant (HSCT) including hematologic malignancies and all forms of primary immunodeficiencies. ProTcell is currently being studies in two clinical trials in Europe, with two in the U.S. expected to start in Q4 2021. To learn more, please visit http://www.smart-immune.com

Media/Investor Contact

Media Contact

Jason Wong

Clare Evans

Blueprint Life Science Group

Smart Immune

jwong@bplifescience.com

clare.evans.ext@smartimmune.com

Read the original here:
Smart Immune Announces Acceptance of Two Abstracts Covering Preclinical Research and Clinical Data at the American Society of Hematology - Yahoo...

Read More...

A dangerous parasite could be used to treat cancer new research in mice – The Conversation UK

November 7th, 2021 1:55 am

A parasite commonly found in cats faeces might one day help treat cancer. My colleagues and I have discovered that the parasite that causes toxoplasmosis a condition that can be harmful to pregnant women and those with a suppressed immune system might be useful at destroying cancer tumours. At least, thats what our study in mice suggests.

For many years now, researchers have been looking at how they can use the bodys immune system to treat cancer known as immunotherapy. This is because, alongside protecting us from the harmful effects of bacteria and viruses, our immune system also rids the body of abnormal cells, such as cancer cells. But sometimes these cancerous cells and tumours can develop techniques for evading the bodys immune system, which means that the immune system wont kill them, and theyll be allowed to grow and replicate.

One type of immunotherapy is immune checkpoint blockade therapy. Our immune system contains a number of so-called immune checkpoints that prevent it from destroying healthy cells. But cancer cells can also avoid destruction by taking advantage of this on/off switch. The checkpoint can shut down immune cells called T cells and suppress the immune response. This is how some tumours are able to avoid being destroyed by the immune system.

Immune checkpoint blockade therapy works by blocking the checkpoint proteins from binding with their partner proteins and sending the off signal. This means that the cancer cells will become visible to the T cells, which can then go about destroying the tumour.

While immune checkpoint blockade therapy has shown promise in treating many types of cancer including lung cancer and melanoma this type of therapy, and many other immunotherapy treatments, dont work very well on so-called cold tumours. These difficult to treat tumours are surrounded by cells that suppress the bodys immune response, which means immune cells wont know how to attack it. Types of cancers where cold tumours are common include breast, ovary and prostate cancers.

But our latest research has discovered a method that could improve the treatment of these cold tumours and it involves using the parasite that causes toxoplasmosis, a relatively common condition that people catch from the faeces of infected cats or infected meat. While its typically harmless and often only causes mild flu-like symptoms, it can be serious in pregnant women and those who have a compromised immune system.

Toxoplasmosis is caused by the Toxoplasma gondii parasite. The reason we chose T. gondii is because it is very infectious and has been shown to infect many species of warm-blood animals including humans. The pathogen is also very tough, secreting proteins that prevent the bodys immune system from acting ultimately ensuring its own growth, replication and survival. We figured that all these attributes would allow T. gondii to trigger a strong immune response if administered directly into a tumour in the hope that would be enough for the immune system to kill the cancer.

Using the gene-editing technology Crispr, our team engineered a strain of Toxoplasma gondii that lacked the protein that causes disease. We then injected this mutant strain directly into melanoma tumours in mice. We later tested it on colon and lung cancer tumours as well.

We were able to show that injecting the live parasite directly into a cold tumour was able to trigger a strong immune response in mice. We were also able to show that even nearby tumours, which hadnt been injected, had an increased immune response.

While previous studies have shown that Toxoplasma gondii can be used to treat tumours in mice, our study took this finding one step further. We showed that when this engineered parasite was used alongside immune checkpoint blockade therapy, tumour growth was significantly suppressed. The eight mice given dual therapy in the early stages of melanoma saw their tumours shrink significantly, whereas treatment with only immune checkpoint blockade therapy failed to cause any regression in the injected tumours in mice.

We also showed that the dual treatment was far more effective at not only shrinking tumours but also improving the survival rate of mice when compared with using immune checkpoint blockade therapy alone. All eight mice who only received immune checkpoint blockade therapy died within 39 days while seven out of eight mice who received the dual treatment were still alive after 60 days. We also saw an increase in a number of different types of helpful immune cells which ultimately improved the response of melanoma tumours in particular to treatments.

Our research joins a body of evidence that parasites including the canine tapeworm Echinococcus granulosus can work against different types of cancer. Bacteria, viruses and bacteriophages (viruses that attack bacteria), are also being trialled as potential cancer treatments.

Its important to note that this study is only in mice, and it will take many years and many more studies before we know if this therapy works in humans. Nevertheless, its an exciting step in the right direction and adds to the growing evidence base that pathogens might be helpful tools in our fight against tough-to-treat cancers.

Read more:
A dangerous parasite could be used to treat cancer new research in mice - The Conversation UK

Read More...

Unexpected Antibody Type Discovered In Individuals With Malaria; New Insights Into Immune Response Against Disease [Study] – IBTimes India

November 7th, 2021 1:55 am

Facts about RSV and HMPV

When it comes to mosquito-borne diseases, malaria is among the worst. It claims thousands of lives annually worldwide and is widely considered an infection of the blood and liver. Also, the antibodies produced in response to the disease are well documented. However, scientists have reported the detection of an unexpected antibody produced against malaria in infected individuals: one that is made primarily in response to infections of the mucous membranes of different organs.

Through a multi-institutional study, researchers discovered the production of IgA (Immunoglobulin A) antibodiesthat are produced when the mucous membranes of organs such as the lungs are infectedin individuals infected with malaria. The study also found that the levels of IgA produced in children and adults in response to parasitic infection varied significantly.

"Not much had been done to study IgA antibodies in malaria infections, because people had not thought that they were important. Yet, because we were not looking for them, we may have missed a whole avenue of research that we can now explore," said Dr. Andrea Berry, corresponding author of the study, in a statement. The findings were published in the journal NPJ Vaccines.

Female anopheles albimanus mosquito (Representational Picture)Pixinio

Malaria is caused in human beings by five parasitic protozoa from the Plasmodiumfamily. They are transmitted through the bites of infected female Anopheles mosquitoes that serve as the primary vectors. Two of these protozoansPlasmodium falciparumand Plasmodium vivaxpose the biggest threats.

Several complications arise due to malaria. This includes damage to organs such as the kidneys and the liver, and can also result in the rupturing of the spleen. According to the World Malaria Reportreleased by the WHO in 2020, there were 229 million cases of malaria in 2019. The estimated number of deaths due to malaria was approximately 409,000 in 2019. Children below the age of five accounted for 67 percent (274,000) of all malaria deaths.

Different types of antibodies are produced by the immune system to help fight infections, and also to prevent reinfection. In older research, the authors had studied other antibody responses in patients with malaria. As expected, antibodies IgG (Immunoglobulin G), which is the most abundant antibody, and IgM (Immunoglobulin M), an antibody that appears during the initial phases of several infections, were detected.

Colorized scanning electron micrograph of red blood cell infected with malaria parasites, which are colorized in blue (Representational Picture)Flickr/ NIH Image Gallery

However, they also chanced upon an unexpected antibodyIgA (Immunoglobulin A). This was uncharacteristic as these antibodies are mostly produced in response to infections in the mucous membranes in areas such as the intestines, lungs, and vagina, among others. Therefore, the researchers chose to conduct a follow-up study to investigate additional samples for confirming their discovery and to scrutinize more groups of participants.

For the current study, the team examined antibody responsesboth IgG and IgAagainst P. falciparum in blood samples obtained from participants constituting three cohorts. The first group was composed of 32 individuals who had been infected through mosquito bites. Blood samples were collected on 1, 15, and 29 days post-infection.

The second group consisted of 22 volunteers who were challenged with the infection through direct intravenous (IV) introduction of P. falciparum. Blood samples were collected on 1, 29, and 57 days post-infection.

Red Blood Cells (Representational Picture)Wikimedia Commons

In addition to the two volunteer groups, the authors also collected samples from 47 childrenbetween the ages of one to sixliving in Mali, West Africa. These children were part of a malaria vaccine trial and their infections were naturally acquired during the course of the study.

Through their analysis, the researchers learnt that adult participants infected with malaria had high levels of IgA antibodies. The vaccine trial group consisting of Malian children exhibited a reduced prevalence of IgA antibodies. They also showed variability in the antigen specificity. However, ten children from the cohort had IgA antibody levels that were similar to those observed in adult participants.

The team also noted that patterns of IgG response were different between the three groups. Nevertheless, despite these variations, IgG antibodies were found to increase among all three cohorts. One question, however, remains to be answered: What leads to the development of IgA antibodies in malaria patients?

A mosquito biting a person (Representational Picture)Pxfuel

"We do not know what triggers the IgA antibodies to develop, but we think it happens early in a malaria infection. Some people think that the response might happen when the mosquito injects the parasiteinto the skin. Interestingly, some of our participants were not bitten by mosquitoes because their malaria infection was delivered intravenously, so there are probably additional triggers for IgA development," stated Dr. Berry.

It is not certain why the levels of IgA in children were not universally high. Dr. Berry averred that several reasons could be responsible for the differing levels of IgA. "Perhaps, children's immune systems respond differently to the parasite than adults do, or it is possible that IgA antibodies are only created during the first malaria infection," she posited.

Children (Representational Picture)Stocksnap.io

Deliberating on other potential reasons, Dr. Berry explained that the team was aware that the adult participants had received their first infection. However, it was not known whether the children in the vaccination trial had been infected previously.

While the timing of the infections and collection of samples among the adult volunteers was uniform, it was not the case among the child cohort. This was because their malaria infectionsoccurred coincidentally during the course of the study.

Dr. Berry added that tests can now be carried out to ascertain whether IgA antibodies prevent malaria parasites from entering red blood cells or the liver. She also said that the proteins which are targeted by IgA antibodies can be investigated and it can be gleaned whether they can be used in vaccines.

See more here:
Unexpected Antibody Type Discovered In Individuals With Malaria; New Insights Into Immune Response Against Disease [Study] - IBTimes India

Read More...

New Preventative Medicine Facility Wraps Work in NYC – Healthcare Construction and Operations News

November 7th, 2021 1:54 am

By HCO Staff

NEW YORK CITYWare Malcomb, an award-winning international design firm, recently announced construction is complete on Princeton Longevity Center, a preventive medicine facility located at 1 World Trade Center. Ware Malcomb provided the interior architecture and design services for the project.

The 10,000-square-foot facility is a new build-out that includes a 2,000-square foot-imaging-diagnostic licensing suite, including advanced technology imaging rooms and a CT scan room. The space also includes a reception area, a lounge, individual patient rooms, exam rooms, offices, and a fitness room. The design is hospitality-focused and mirrors the aesthetic established at their Princeton, New Jersey location.

Princeton Longevity Center is extremely patient-centric in all of their decisions, said Marlyn Zucosky, Regional Director, Interior Architecture & Design for Ware Malcomb. We were pleased to work closely with them to design a facility to enhance their patients experience and wellness. The result is a highly-functional, relaxing and beautiful space in one of the worlds highest-profile buildings.

At the entrance to the suite, a virtual receptionist assists guests with check-in. The inviting lounge offers spectacular views from the 71st floor of the 1 World Trade Center and incorporates wood-look luxury vinyl tile flooring, as well as a curved reception desk with backlit features. A custom hand-woven rug, a unique light fixture and a custom millwork coffee bar add a hospitality vibe to the spacious waiting area.

Individual patient rooms provide guests with a private space while they spend the day at Princeton Longevity Center and include computers, showers and a relaxing lounge atmosphere. The exam rooms and doctor offices, which also provide views of the city, incorporate calming colors. The rich tones of the design color palette are a dramatic contrast to the natural light provided by floor-to-ceiling windows.

The general contractor was Icon Interiors, Inc. The project achieved LEED Gold certification, a requirement of all 1 World Trade Center tenants. This is Ware Malcombs second project for Princeton Longevity Center; the first was their Princeton, NJ location, completed four years ago. Princeton Longevity Center is a leader in the preventive medicine market, offering the most advanced technology services and serving C-suite clientele with comprehensive medical evaluations.

Here is the original post:
New Preventative Medicine Facility Wraps Work in NYC - Healthcare Construction and Operations News

Read More...

MPD working with faith-based leaders to fight violent crime – FOX13 Memphis

November 7th, 2021 1:54 am

MEMPHIS, Tenn. Across Memphis, there have been at least 270 homicides compared to 263 at the same time last year. With less than two months left in the year, the city is on pace to shatter last years record.

In an effort to slow things down, MPD is working on getting to the source of violent crime.

Faith-based leaders have partnered with law enforcement to offer resources. The goal is for officers not just to respond to crimes but also to stop them before they start.

Preventative medicine is the best form of medicine, said Pastor Ricky Floyd with Pursuit of God Church.

To cure a city plagued by violent crime, the Memphis Police Department has partnered with faith-based leaders to get to the root of the problem.

Couples counseling, trauma response, gang talk, domestic violence, conflict resolution. Those are some of the things problematic in our community, said Memphis Deputy Police Chief PaulWright.

Faith-based leaders, MPD, and the U.S. Attorneys Office are hosting the Better Community Summit Saturday. The aim is to connect attendees with experts who specialize in areas Wright described.

Young people have seen things happen in their community now that they dont quite understand.If they dont get that fixed, it may be a problem in the future, Wright said.

Floyd said this summit is vital to lift the community.

Sometimes people think no one is out there to help me. Theres a lot of help available, said Floyd.

The summit isSaturday from 10 a.m. to 2 p.m.at Pursuit of God Transformation Center in Frayser.

CLICK HERE TO DOWNLOAD

Trending stories:

2021 Cox Media Group

Read more from the original source:
MPD working with faith-based leaders to fight violent crime - FOX13 Memphis

Read More...

Cornell grad and lecturer touts benefits of plant-based diet – ithaca.com

November 7th, 2021 1:54 am

If there is one piece of advice that 87-year-old Dr. T. Colin Campbell would give to those looking to age well and stay healthier longer, it would be to change your diet to a plant based, whole food approach.

The idea of plant based eating has gained popularity in recent years, but it was first coined by Campbell back in 1978. The bestselling coauthor of The China Study (published in 2006) said it has been exciting to see it gain traction in the last several years.

Its interesting because the idea of a plant based diet possibly being the best and the way of the future is just beginning to take hold in the mainstream public, Campbell said.

His recommendation that most everyone can adopt a plant based diet and have it benefit their lives hinges on a discovery he made early in his career: that people do not need to eat animal protein in order for their bodies to get the protein they need.

For the son of a dairy farmer, this flew in the face of what he had believed growing up but the evidence that a plant based diet can prevent and, in the vast majority of cases, even reverse common American ailments like diabetes, high cholesterol and heart disease was so strong that he dedicated his career to researching it and publicly sharing his findings. He has also worked to shape public policy around health and nutrition and was the liaison to Congress for the medical research community in 1980 and 1981.

Campbell wasnt always interested in studying nutrition. He was completing his first year of veterinary school when he received a telegram from a well known Cornell Professor offering him a scholarship and research opportunity, which led him to complete his education at Cornell University and MIT in the field of nutrition, biochemistry and toxicology. During his time at Cornell, around 1965, he was tasked with coordinating an effort to aid malnourished children in the Philippines. It was believed at the time that the children needed more animal protein to be healthy, but what Campbell found instead was that the few children who came from families who were able to consume more animal protein had a higher rate of liver cancer than their peers.

I couldt quite believe what I was seeing, Campbell said. I had many students work in the lab on this question and over the years found that there is no need to consume animal food to get that protein. That is totally false.

Campbell spent a decade on the faculty of Virginia Techs Department of Biochemistry and Nutrition, then returned to Cornell in 1975, where he currently holds his endowed chair as a professor emeritus of nutritional biochemistry in the Division of Nutritional Sciences.

In recent years Campbell founded a non-profit organization on online learning in nutrition which recently developed, under the direction of Campbells daughter LeAnne Campbell, the program Plant Forward, which holds online workshops.

The workshops teach a simple philosophy that can be difficult to put into practice at first but pays great dividends if the individual can stick with it for a month or two, Campbell said.

The people who stay with it are often people who have a serious health problem or have a motivation, he said. Sometimes the effects are almost immediate.

People can see their blood sugar drop precipitously in one day, he said. Its amazing.

The key is to go all-in on the new diet. He likened it to quitting smoking just cutting down to one or two cigarettes per day or smoking on some days but not on others is not likely to lead to success in the longterm. But soon, Campbell said, this new kind of eating will become second nature and even enjoyable.

Youll all of a sudden discover you crave a salad, he said. Just eat vegetables, grains, nuts, and avocados for the oil and fat.

As much as possible, stay away from added oils and refined carbs, he added.

The effects of adopting a whole plant-based diet are striking, he said.

We can turn experimental liver cancer genes on with animal based protein and turn it off by eating a plant based diet, he said.

Campbells own father died of a heart attack when he was 70, and his wifes mother died of colon cancer when she was just 51. That motivated us to think about changing our diet, so we did, he said. His wife is 80 years old, and both are largely medication free other than a short period Campbell spent on medication to control his blood pressure.

Campbells first book, The China Study, came out of a partnership in the 1980s with researchers at Oxford University and the Chinese Academy of Preventative Medicine and sold nearly four million copies worldwide. Campbell followed that up with his second book, Whole, in 2013, which is focused on the science behind plant based eating.

In 2020 he published The Future of Nutrition: An Insiders Look at the Science, Why We Keep Getting it Wrong, and How to Start Getting It Right.

He still gives lectures and is involved with the online Plant-Based Nutrition Certificate in Partnership with eCornell. His research is the cornerstone of the 2011 documentary film Forks Over Knives, and his oldest son, Nelson Campbell, made another popular documentary on the topic called Plant Pure Nation.

Some advice that he received from his father that has guided him throughout his life: Tell the truth, the whole truth, and nothing but the truth. It is a philosophy that allowed him to question his original assumption that eating animals must be good for health.

The key is to be honest with yourself and check your own biases, he said. Thats really critical.

See original here:
Cornell grad and lecturer touts benefits of plant-based diet - ithaca.com

Read More...

Meet the Cork-born bread activist who has Goldie Hawn buying her loaves – Irish Examiner

November 7th, 2021 1:54 am

Karen ODonoghue has a goal: to cure everyone in Ireland of IBS. And, paradoxically, shes aiming to use bread to do it.

Already you can see the bands of gastroenterologists around the country tut-tutting at such a tall order.

Yet, ODonoghue should know a thing or two. In 2018 she was named Gut Specialist of the Year in the UK and she is currently a judge for the World Bread Awards.

Actress Goldie Hawn rates her anti-inflammatory bread so highly that she took ten loaves with her back to the US and claimed it cured both her and her sons Irritable Bowel Syndrome (IBS).

Ears perk.

Every system and organ in the body is dependent on the health of the gut microbiome so when you nourish the microbiome, it automatically nourishes the brain, says ODonoghue from her new bakery in Mayo.

Youll make better decisions in your life, have more energy, and youll enjoy better sex, she adds, with a twinkle.

Eyebrows raise.

Bread activism it kind of has a ring to it.

And this is the business ODonoghue is in, swapping prescriptive medicine for a food-led approach to managing and healing ones own body.

As the founder of the Happy Tummy Company in London in 2014, she is responsible for single-handedly pioneering a scientifically-developed range of breads aimed at alleviating IBS (her UK customers coined the term magic poo bread for how much it helped them), mental health issues, period and menopause pain, and, what she describes as functional rehab for both physical injury and trauma from illness.

The Happy Tummy Company was born out of a deep desire to help others, and in turn, out of illness.

Growing up in Cork where her parents ran a horticulture company, when ODonoghue was 10 years old her mother was diagnosed with cancer.

She vividly remembers the lightning bolt moment that would dictate the course of her future.

Growing up with a mother who had cancer and who ultimately died from it, I was very aware of the part food had to play in our overall wellbeing.

During the time of my mums cancer treatments I remember digging the soil with my dad, planting beech saplings, and I had this epiphany: when Im older Im going to create a brand thats all about food as preventative medicine.

Fast forward to 24-year-old Karen living in London.

Having spent most of her life battling with IBS, she found herself depressed and anxious.

The older I got and the more my IBS became an issue, I knew I needed to go back to that ambition I had as a little girl. Intuitively I always knew that food is medicine.

She started poring over scientific research papers to learn about the gut microbiome and discovered that our gut bacteria works to a specific mathematical equation: we should be eating 66% dietary fibre to 33% dietary protein and five grams of prebiotic fibre every day.

Based on this, she created her own formula (her father was a maths teacher they regularly discussed theorems at the dinner table) and applied it to the bread making process.

It was during this time that she discovered a gluten-free grain from Africa.

The star ingredient is teff, grown in Ethiopias highlands, which is high in protein, calcium and iron, along with prebiotic fibres and antioxidants, all of which stimulate the growth of good gut bacteria, reduce inflammation and nourish the lungs, brain, skin, and nervous system. Teff relieves bloating and constipation and also helps to balance hormone levels, stimulate digestion and strengthen bones.

After 18 months of a mad scientist-like existence in her London flat she developed a loaf of bread that would completely rid her of her IBS.

From having one bowel movement every three weeks, within a week she was doing two poos a day.

The shape of her tummy changed, her depression and anxiety disappeared and she started to feel alive again.

That loaf is now her best-selling Chia Teff Loaf, aka the magic poo bread

In 2014 she established her London bakery, The Happy Tummy Company (cue Goldie Hawn and many more high-profile followers) in Hackney and a school where she taught students how to use food both as preventative and prescriptive medicine.

The bread-making process started as a means to cure her own IBS but once the word got out, loaves were flying off the shelves like IBS-crusading hotcakes.

Last year, after 13 years in the UK, she decided to relocate the business headquarters to Westport in Mayo.

ODonoghue walks the talk. She beams of health and is genuinely positive, which is infectious to be around.

ODonoghue believes we need to pare back how we look at bread and start viewing our consumption of it primarily from a health perspective, and flavour as a secondary issue.

The reason bread has a branding problem, she believes, is because bakers are obsessed with the aesthetics of what they are making over nourishment, creating white, fluffy sourdough breads using commercial wheat.

Consumers, particularly those who have issues with gluten or coeliac disease, eat these breads and all of a sudden feel bloated, lethargic, and agitated. And thats not surprising.

You are eating a wheat that is not very natural.

The Chia Teff Loaf takes about three days to make and is packed with organic teff (so no herbicides or pesticides), sprouted buckwheat, walnuts, Brazil nuts, almonds, linseed, and chia seeds all expensive ingredients.

It costs 25 per loaf.

As a bakery we are not yet making money and Ive had to fight an industry that has brainwashed people into thinking that food can be cheap.

I know its generally not politically correct to go so hard on this organic way of eating because people will argue that it is elitist, privileged and only a certain percentage can afford organic food.

But when I had the bakery in Hackney we had loads of customers who were on the breadline buying our bread because they fundamentally understood the importance of organic, wholegrain food in their diet.

This month ODonoghue launches her 48-hour soaked wholegrain Chia Teff Loaf, aka the magic poo bread, to the Irish market on a nationwide delivery service.

She also runs baking classes at her school house, Teach Scoile, in Westport to educate people on the benefits of teff.

As a baker, she separates bread makers into two camps.

There are those who nourish, and there are those who feed, she says.

And Ive always wanted to nourish.

When I had that epiphany at 10 years of age I knew that this brand will be more of a vocation than a business.

What Im doing here is a vocation about preventative medicine to give every single person suffering with IBS access to food and education that works.

Link:
Meet the Cork-born bread activist who has Goldie Hawn buying her loaves - Irish Examiner

Read More...

Pfizer says pill cuts risk of severe Covid by 89% – RTE.ie

November 7th, 2021 1:54 am

A trial of Pfizer's experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalisation or death for adults at risk of developing severe disease, the company said.

The results appear to surpass those seen with Merck's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalised for Covid-19 patients also at high risk of serious illness.

Full trial data is not yet available from either company.

Professor Luke O'Neill said the new drug is "very significant" because the manufacturer got 89% efficacy in their trial.

The Trinity immunologist added: "What that means is 9 out of 10 people wouldn't end up in hospital with Covid. If that turns out to be true once it's launched that would be remarkable.

He said this disease is an emergency and Pfizer is applying for emergency use in the United States with the FDA and also with the European Medicines Agency (EMA).

"Those agencies will look very closely at the data and the safety and they will be really under pressure now approve these drugs because an antiviral is a great extra weapon to use against this virus," Prof O'Neill said.

Separately, the Tnaiste has said a new antiviral oral pill for Covid will be a "very valuable weapon" and he hopes it can be approved by the EMA "quite soon".

Yesterday, the UK medicines regulator became the first to approve the drug 'Molnupiravir', for people who have had a positive Covid test and have at least one risk factor for developing severe illness, such as obesity, being over the age of 60, diabetes or heart disease, something Leo Varadkar said was "really encouraging".

Mr Varadkar said: "Once you are diagnosed you can take this tablet and it reduces by up to half the chances of you needing to be hospitalised, so that can really make a big difference.

"I hope the EMA will approve that quite soon, because you can never deal with a virus through vaccination alone, you need therapeutics too and you need preventative medicine.

"This is going to give us an extra weapon in our armoury and a very valuable weapon too," he added.

Pfizer will now submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the US Food and Drug Administration as part of the emergency use application it opened in October.

The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.

A spokesperson from Pfizer in Ireland said that the company's plant in Ringaskiddy "will support the global manufacturing and supply" of the drug, if it is given approval.

He said: "Pfizer has begun investing prior to regulatory authorisation in the manufacture of our potential Covid-19 oral antiviral candidate to help bring this potential treatment to patients as soon as possible.

"Pfizer's site in Ringaskiddy has a successful history of contributing to our manufacturing efforts."

We need your consent to load this rte-player contentWe use rte-player to manage extra content that can set cookies on your device and collect data about your activity. Please review their details and accept them to load the content.Manage Preferences

The planned analysis of 1,219 patients in Pfizer's study looked at hospitalisations or deaths among people diagnosed with mild to moderate Covid-19 with at least one risk factor for developing severe disease, such as obesity or older age.

It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalised and none had died by 28 days after treatment.

That compared with a hospitalisation rate of 7% for placebo patients. There were also seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalised, compared with 6.7% for the placebo group, which included ten deaths.

Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.

"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective," said Annaliesa Anderson, head of the Pfizer programme.

The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.

"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients' lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalisations," said Pfizer Chief Executive Albert Bourla.

Infectious disease experts stress that preventing Covid-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.

Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.

Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus.

Merck has already sold millions of courses of the treatment, which was approved this week by UK regulators, to the US, the UK and others.

Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.

Pfizer is also studying whether its pill could be used by people without risk factors for serious Covid-19 as well as to prevent coronavirus infection in people exposed to the virus.

Read more:
Pfizer says pill cuts risk of severe Covid by 89% - RTE.ie

Read More...

The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm – Yahoo News

November 7th, 2021 1:54 am

A supporter of President of Brazil Jair Bolsonaro waves a box of ivermectin at a pro-government demonstration in Brasilia in May 2021. Andressa Anholete/Getty Images

The popularity of unproven anti-parasitic drug ivermectin as a COVID-19 treatment is surging.

Its use has roots in South America, where it was hyped by populist leaders citing debunked research.

"Nobody paid attention... now we see the same" in the US, a Peruvian official told Insider.

In May 2020, when the coronavirus was sweeping the South American nation of Peru, Dr. Patricia Garcia of the country's health ministry began receiving disturbing reports from the country's hospitals.

They detailed injuries not caused by COVID-19, but a drug people thought would help them: the anti-parasitic substance ivermectin.

"The kind of things they were telling was people that were coming with severe gastritis [stomach inflammation], and also pancreatitis, because they were taking the ivermectin in desperation," Garcia told Insider.

As the coronavirus continued to spread, people's faith in ivermectin as a way out of the crisis grew more fervent, said Garcia.

It would be almost a year before ivermectin would become widely discussed in the US, as a subset of Americans began to insist on receiving it.

The US demand for ivermectin surged as vaccination - the most effective COVID countermeasure - became increasingly politicized. Doctors strongly advise against taking it but, as of October 16, more than two-dozen lawsuits had been filed around the US from people demanding access to it.

"History is repeating," said Garcia. "Nobody paid attention about what was happening in Latin America and now we see the same situation."

A municipal worker sprays disinfectant past a street vendor at a market in Puno, Peru, near the border with Bolivia, on June 10, 2020. CARLOS MAMANI/AFP via Getty Images

In the Peru of May 2020, there were no vaccines, and ivermectin's rise was being driven by hope and desperation.

Pharmacies fast ran out of pills as thousands sought to obtain it, and a lucrative ivermectin black market emerged, as local media reported at the time.

Adherents recommended both that healthy people take ivermectin as a preventative, and that it be used to treat COVID-19 after infection.

Story continues

Many resorted to a stronger version of the drug, normally used to deworm horses. That form is taken by injection, and people who took it were left with serious skin lesions, said Garcia.

As the fervor spread, evangelical groups based in southern Peru injected 5,000 people from indigenous communities with the drug.

In some cities, including the capital, Lima, public health officials distributed the stronger, dangerous form of the drug to whole neighborhoods.

The belief that ivermectin could work against COVID-19 is almost as old as the pandemic, predating vaccines and even proper testing.

Almost two years later, there is still no conclusive evidence that ivermectin is effective against COVID-19, and it has been repeatedly debunked, including by the FDA in September.

It said that taking large doses of any kind of ivermectin is dangerous, and that humans should never take drugs intended for treating animals.

Carlos Chaccour, a researcher at the Barcelona Institute for Global Health, pointed to an obscure research paper in early 2020 which appeared to answer the desperate desire for a workable treatment.

The paper drew on data from Surgisphere Corporation, a small research group in Chicago, which published it in April 2020 seeing to establish a link between taking ivermectin and surviving COVID-19.

A pharmacist in Santa Cruz, Bolivia, with doses of ivermectin. Rodrigo Urzagasti/picture alliance via Getty Images

The researchers, who also touted hydroxychloroquine, said the paper's basis was data from thousands of hospitals around the world. Their research was published by top-tier medical journals including The Lancet and The New England Medical Journal.

But doubts soon emerged the authenticity of Surgisphere's data, the credentials of its team, and the methodology they used.

The Lancet and The New England Medical Journal retracted the study after a backlash from the scientific community and an investigation by The Guardian. But by then, said Chaccour, the damage was done.

In summer 2020, government officials in Peru, Bolivia, and Guatemala made ivermectin part of their COVID-19 strategies, often citing the retracted study as evidence.

Chaccour told Insider that the drug was embraced so readily because it seemed to present a simple solution, was relatively cheap, and was already widely used in the region.

He noted that a danger of the drug - perhaps worse than its adverse effects - was that people who believed it to be effective against COVID-19 were more likely to ignore actions that actually work.

"One of the risks of ivermectin is not just the safety, but the hazard of people not using masks or not getting vaccines or not doing social distancing because they think they are protected," he said.

As a second wave of the coronavirus hit South America in the latter half of 2020, ivermectin became more popular still. The city of Cali in Colombia handed it out to all of its COVID patients in late July. Weeks later the state of Chiapas in Mexico followed suit.

In Brazil, South America's most-populous country, the drug was endorsed by the country's populist president, Jair Bolsonaro, and by his allies at a regional and national level.

But it wasn't just politicians. They were riding a wave of social-media misinformation that was still spreading. In groups on Facebook and WhatsApp, misinformation about ivermectin was being shared by millions, experts told Insider.

Among its influential promoters was COMUSAV, a group of renegade medics based in Bolivia, whose core product was a kind of industrial bleach promoted as a miracle cure for a vast array of ailments that included COVID-19.

They pushed ivermectin to their followers across the continent on their Facebook pages, which had tens of thousands of followers.

(Many of the group's pages were removed following an investigation by Insider in March 2021.)

A data analyst, Juan Chamie, was among those who helped to bring the enthusiasm for ivermectin from the populists of South America to their equivalents in the US, experts told Insider.

Chamie claimed to have data showing lower COVID-19 mortality in parts of South America where public health authorities approved ivermectin.

But Chaccour and data scientist Joe Brew have said his analyses are misleading, and ignore other factors that could explain the differences.

"Just because things are associated does not necessarily mean that one thing causes the other," they said.

That hasn't stopped Chamie's analyses being shared widely, until his account was suspended by Twitter.

Among those taking note was Laura Ingraham, primetime host of Fox News' show "The Ingraham Angle."

In December 2020 Ingraham posted a graph of data attributed to Chamie to her 3.8 million followers.

It purported to show a reduction in COVID-19 cases, comparing areas of Chiapas, Mexico, where officials did and did not distribute ivermectin.

Chaccour said that, as with Chamie's other claims, the decrease could be coincidental or due to other factors.

Ingraham already had a history of promoting ivermectin. As far back as March 2020, Ingraham had tweeted about the Surgisphere research that was later debunked.

Chaccour believes that Ingraham's advocacy was a tipping point for ivermectin in the US.

Progressive campaign group Media Matters noted that Ingraham's enthusiasm extended to her widely-viewed Fox News show.

In two episodes in December 2020, Ingraham claimed that medical authorities were conspiring to suppress the substance and ignoring evidence of its effectiveness. Andrew Lawrence, a Media Matters staffer, told Insider that Ingraham was "definitely the leader" among network hosts promoting the substance.

A Fox News spokesperson said in Ingraham's defense that she never explicitly told viewers to take the drug.

In comments to The Washington Post, Ingraham criticized attempts to "silence" scientists with unorthodox messages. "Just like the scientific consensus, the medical consensus is evolving. It changes," she sad.

Chamie also formed contacts with the Front Line Critical Care Alliance (FLCCA), a group of US medics who were influential in pushing ivermectin in the US, as detailed in a September investigation by Insider's Hilary Brueck.

Chamie describes himself as a senior data analyst for FLCCA on his LinkedIn page, and the group cites his research on its website.

The group has been instrumental in brokering ties between the pro-ivermectin movement and Republican lawmakers who promoted the drug.

Last December, Dr Pierre Kory, a member of the group, testified before the US Senate about ivermectin in what one critic, Brown University dean Dr. Ashish Jha, described in The New York Times as a "misinformation super-spreader event."

In a statement to Insider, the FLCCC defended its position on ivermectin, forwarding Insider a list of studies based on anecdotal evidence suggesting that ivermectin may be effective in reducing COVID-19 deaths. These studies are not considered conclusive by experts.

The group did not respond to questions regarding Chamie's research, and Chamie himself did not respond to requests for comment from Insider.

As proponents in the US clamored for wider use of ivermectin, in South America disillusioned officials were reversing their position.

In February Peru removed ivermectin from its COVID treatment protocol altogether because of the absence of evidence that it worked.

"It's incredible for me that we, a whole region, already went through this terrible situation in which lots of people have died," Garcia, the Peruvian official, told Insider.

"They were taking ivermectin because it was known to us, so it was easy for us. And it didn't work."

Read the original article on Business Insider

Read the rest here:
The roots of ivermectin mania: How South America incubated a fake-medicine craze that took the US by storm - Yahoo News

Read More...

Prior poor mental health linked with higher rates of COVID- study – The Jerusalem Post

November 7th, 2021 1:54 am

Several studies have shown that the pandemic took a devastating toll on peoples mental health and impacted other psychiatric conditions, but a novel study looked at things from a different perspective.The investigation, conducted by Yale School of Public Health and published in the American Journal of Preventative Medicine, looked at US nationwide levels of mental health to establish that those with poor mental health prior to the pandemic have a greater likelihood of developing a COVID-19 infection.

Researchers used aggregated data from a survey conducted across 2,839 counties to conclude that between 2010 and 2019, a total of 2,172 counties (77%) experienced significant increases in the average number of poor mental health days, including depression, stress and problems with emotions.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

Further research revealed that more days of poor mental health in 2019 had a robust association with the rate of COVID-19 infections in 2020, leading researchers to believe that the pandemic did not cause new mental health problems, but rather revealed previously ignored issues.

Analysis revealed that poorer mental health days and COVID rates were driven by a few states-- Arizona, Montana, and Nevada.

Lead investigator Yusuf Ransome expressed hope that the study will encourage conversation about the urgency of mental health care.

We call for policies that strengthen surveillance systems to better capture a range of mental health outcomes in the population, address social inequalities that give rise to poor mental health, and [increase] funding to create, sustain and equitably distribute mental health resources, including wellness care centers across US communities," he said.

Ransome added that the idea for the study was inspired by the height of the pandemic.

"Only a handful of studies examining small fragments of the population had considered the possibility that poor mental health could be contributing to a higher burden of infection rather than vice versa," he said. "We wanted to examine whether these relationships also existed in the general population, address the lack of studies with an ecological-level focus, and produce evidence to strengthen calls for interventions.

Continue reading here:
Prior poor mental health linked with higher rates of COVID- study - The Jerusalem Post

Read More...

The pandemic exposed Montreal’s inequalities, and residents say it’s time to tackle root causes – CBC.ca

November 7th, 2021 1:54 am

What was long suspected was quietly confirmed last month: Montrealers who live in the city's poorest neighbourhoods were more likely to die from COVID-19 at the height of the pandemic.

Now community organizers and experts are turning to how to best address the underlying issues that contributed to the disproportionate impact of the pandemic on the city's lower income, more racialized neighbourhoods.

"It really sheds light on the fact that social inequalities here since long before the pandemic are still here and need to be addressed," said Vronique Nadeau-Grenier, the lead researcher on the study conducted by Montreal public health.

The study, released Oct. 13, found a clear correlation between a neighbourhood's material advantages a metric which includes education and income levels and COVID-19 mortality rates.

The public health agency recommended a multitude of changes to address the underlying disparity in the city.

Some of them can be addressed by the City of Montreal, which is set to hold its municipal electionNov. 6 and 7, and others are more complex issues that involve several levels of government.

They include an increase in pay for low-wage workers and the fostering of more stable workplaces (movement between healthcare workplaces was an early contributor to the spread of COVID-19 in Quebec), increase to the availability of affordable quality housing and improved access to social and health services in disadvantaged areas.

The findings underscore those laid out in a CBC News analysis last year after the city's first wave.

Vulnerable populations, such as people living in low-income households, with precarious employment and in underprivileged neighbourhoods, represented both the most cases and deaths linked to COVID-19.

On average, underprivileged neighbourhoods had twice the number of cases and deaths than more affluent ones.

Marjorie Villefranche, the head of Maison d'Haiti, a community organization in Montral-Nord, said the numbers confirm what she has been saying for more than a year.

"We kept saying it and no one was listening," she said. Villefranche said the pandemic highlighted the lack of services in the area.

Montral-Nord, the report found, has the highest mortality rate of any sector: three times higher than some parts of the West Island.

The borough also has the highest per capita case count in the city: 12,079 cases per 100,000 people, as of Oct. 28.

Parole d'excluEs and Hoodstock, both of which have been calling for more research on pandemic impacts, released their own survey of residents. The report found a gap in health and mental health services, and the need for improved communication with residents.

"What all this highlights is that there needs to be a massive investment for community-based organizations in these poorer neighbourhoods that would lead to better access to health care and social services," said Olivier Bonnet, head of Parole d'excluEs.

Mabel Carabali,an assistant professor in the department of social and preventative medicine at University of Montreal, who holds adjunct position at the Dalla Lana School of Public Health at the University of Toronto, said such dynamics are visible in many cities.

She said the underlying issues have been "neglected for too long" and they need to be put under the microscope long after the municipal election cycle.

In Montreal, the disparity played out during the first three waves of COVID-19. By the summer of 2021, according to the report, the disparity had subsided with the spread of COVID-19 on the decline.

Nicholas King, a professor at McGill University who conducts research in public health ethics and policy, said it would be useful to dig deeper into the causes of that levelling off.

"That may give us some clues for us intervening in the future to try to reduce inequalities in health," he said.

In the meantime, he said the government should commit to more quickly and consistently reporting on health and social inequality.

King touted community groups in the province for stepping up and into the breach by producing the data themselves when they noticed the lag.

He said while experts and governments rely on public health authorities to understand what should be done next, community groups can benefit from the data themselves.

"Often some of the most effective interventions against inequalities are bottom up."

Originally posted here:
The pandemic exposed Montreal's inequalities, and residents say it's time to tackle root causes - CBC.ca

Read More...

Humans and Hardware: How Special Operations Can Pioneer Wearable Technology – War on the Rocks

November 7th, 2021 1:54 am

In 2009, the U.S. Special Operations Command announced that Humans are more important than hardware. But with wearables revolutionizing sports medicine and athletics, the distinction between humans and hardware is less relevant than ever. This means that investing in wearable technology for special operations forces is now the best way to put humans first.

What might this look like? With a small population of elite warfighters in high-stress environments, Special Operations Command can lead the force in determining which wearable devices are worth the investment. The Preservation of the Force and Family program, which is already in place to improve the holistic health of special operations forces, can spearhead efforts to distribute, monitor, test, and best utilize wearables for the entire military.

A Wearable Revolution

In the last two decades, sports medicine and sports science have advanced dramatically. Athletes are now bigger, faster, and stronger due, in part, to advancements in technologies that allow them to train smarter. A critical facet of this revolution is wearable technology that offers athletes immediate and continuous feedback on an increasing number of health and performance metrics. The wearable trend started with simple Global Positioning System-enabled devices measuring steps taken in a day and heart-rate monitors allowing users to train in specific heart-rate zones. However, wearable technology is now quickly outpacing older, more expensive, and more invasive technologies. New Apple Watches, for example, allow users to bypass hospital visits by serving as both an electrocardiogram to monitor heart health and a pulse oximeter to measure blood oxygen levels in 10 seconds. Wearables rapid development is providing valuable new tools for physical therapists and healthcare professionals and eliciting optimism about the future of individualized self-care.

This revolution hasnt gone unnoticed by the Department of Defense, which is testing wearables across different military branches. The U.S. Air Force recently began using the Oura Ring, a technology worn on your finger, to more accurately determine pilots flight readiness in the morning based on their overall sleep score. Previously, pilots flight readiness was determined by hours in bed rather than the quality of sleep. However, Oura Rings offer the ability to both measure sleep quality and potentially improve sleep, making pilots fitter to fly. Additionally, the U.S. Navy regularly tests various wearable devices at the Naval Postgraduate School Human and Systems Integration laboratory to study and improve crew rest, while the U.S. Army tests wearables to study soldiers resiliency in harsh winter conditions. As wearable technology continues to progress, so do the applications and opportunities to improve service members sleep, fitness, and overall health.

Wearables Potential in Special Operations

In 2012, Special Operations Command adopted the Preservation of the Force and Family strategy. The goal was to optimize and sustain mission readiness, longevity, and performance, thereby maximizing the estimated $1.5 million investment that the military makes in each member of special operations. The strategy seeks to provide precise preventative interventions and emphasisizes holistic health across five domains: physical, cognitive, psychological, social and family, and spiritual.

Wearable technology is already improving individual physical fitness and should be a critical component in enhancing operator health across every all of these domains. Wearables currently track a host of physical and biological metrics and use algorithms to generate useful approximations of additional metrics, including sleep quality, readiness, and stress. Many wearable interfaces offer coaching to nudge users towards healthier behaviors. Leading wearables, including the Oura Ring, Apple Watch, and Whoop Strap, offer nuanced sleep and activity coaching based on users unique metrics and trends. Put simply, wearables can tell you when you are overworked and need a break.

In an organization like Special Operations Command, which demands long hours under highly stressful conditions, having a tool that provides an objective measurement of readiness is uniquely valuable. Operators are specially selected and trained for resilience to adverse physical and mental conditions. Constant adaptation to a changing environment, however, comes at a cost. But this advantageous adaptation can produce allostatic load, leading to chronic physical maladies including pain, fatigue, and compromised immunity. Reduction of allostatic load first requires identification of increased stress. Enter wearables. Wearables can provide feedback on a host of biological metrics correlated with stress, including heart-rate variability, resting heart rate, and sleep quality. This makes it possible to identify chronic physiological stress, implement nuanced interventions, and prevent the difficulties associated with allostatic overload.

Wearables can also bring benefits in the cognitive and psychological domains. The Oura Ring encourages users to monitor body signals through practices such as guided mindfulness and breathing protocols. As shown by ongoing studies at Texas A&M, mindfulness meditations and associated breathing exercises can reduce stress and improve mental health. This can be particularly useful to special operations forces in reducing combat mental illness. Paired with blast gauge data or baseline cognitive tests such as the Automated Neuropsychological Assessment Metrics, wearables may also allow the early identification and treatment of traumatic brain injury.

Mitigating Concerns

In a profession where chronic stress is so abundant that it produced the term operator syndrome, why are wearable technologies not already commonplace? For one thing, there isnt a one-size-fits-all wearable. While one wearable specializes in sleep, for example, it may not be as effective at measuring physical activity. Concerns over operational security also dampen wearable enthusiasm in the Defence Department. And for good reasons in 2018, the fitness and location tracking application Strava infamously illuminated the location of multiple overseas military bases. Similarly, privacy risks regarding collected data can cause hesitation in an increasingly connected and data-driven world. Data security and patient confidentiality are paramount concerns with aggregated health information collected from wearables, and have legal implications under the Health Insurance Portability and Accountability Act. While data is routinely stripped of identifiers, including names and addresses, it can become re-identifiable when correlated with other datasets.

Special Operations Command has an important role to play in helping to address these security and privacy concerns. Letting the Preservation of the Force and Family program lead the development of wearables can help by removing military commanders from the loop, preventing mandatory use and giving participants the power of consent. Personnel associated with this program are also trained and certified to handle protected health information, reducing the risk of a Health Insurance Portability and Accountability Act violation and relieving military commanders of such a burden. Assigning random user identifications can help to avoid the disclosure of personal data. Preservation of the Force and Family personnel can further prevent the re-identification of anonymous users by isolating the wearables data, thereby preventing their merging with larger military data sets.

While there are simple ways to mitigate the known concerns over wearables, there will always be risks, especially with the early adoption of technology. These risks should be explored, preferably in a small and competent population, to best identify and understand wearables capabilities and limitations. Implementation and open dialogue will enable the force to exploit wearables significant potential to improve holistic health.

Wearables Are Coming!

In any technological revolution, there will be resistance to adopting new technology, especially in large organizations like Special Operations Command. Nevertheless, wearable technology has taken the world by storm. Large corporations have adopted wearables into healthcare policies, and wearable tech is an $81.5 billion industry. With a smaller population that is often presented with high chronic stress, Special Operations Command has the opportunity to lead the U.S. military in the use of wearable technology. By leveraging the recent revolution in wearables, programs such as Preservation of the Force and Family can bring humans and hardware together in the safest and smartest way possible.

Maj. Kevin Butler and Maj. Frank Foss are Army Special Forces officers currently pursuing a masters in Defense Analysis at the Naval Postgraduate School. Between them, they have over a dozen combat and operational deployments to the Central Command and Southern Command.

Disclaimer: The views expressed in this article are the views of the authors alone. They do not reflect the official position of the Naval Postgraduate School, the U.S. Army, the Department of Defense, or any other entity within the U.S. government and the authors are not authorized to provide any official position of these entities.

Image: U.S. Army (Photo by Sgt. Apolonia Gaspar)

Originally posted here:
Humans and Hardware: How Special Operations Can Pioneer Wearable Technology - War on the Rocks

Read More...

Halting COVID-19 in its tracks – UBC Faculty of Medicine

November 7th, 2021 1:54 am

Nearly two years into the global pandemic, there remain a handful of approved therapies to treat COVID-19.

Dr. Dermot Kelleher

And with emerging variants threatening the effectiveness of existing vaccines, there is an ever-pressing need to find new treatment approaches to fight the disease.

At UBCs faculty of medicine, researchers Dr. Dermot Kelleher and Dr. Shane Duggan are tackling this challenge head on, redirecting elements of their groundbreaking research on esophageal disease to develop a novel aerosol treatment for COVID-19.

The global effort to intervene in the spread and severity of COVID-19 has produced several effective vaccines, but there is still a pressing need for new treatments for people who contract the virus and to safeguard the health and well-being of those who are most vulnerable to disease transmission, says Dr. Kelleher, dean of the faculty of medicine and vice-president, health at UBC.

The proposed therapyset to be delivered to the lungs as an aerosol using a handheld nebulizerwould be designed to stop the virus from replicating, halting the progression of COVID-19 in an effort to reduce harmful health effects and save lives.

The global effort to intervene in the spread and severity of COVID-19 has produced several effective vaccines, but there is still a pressing need for new treatments for people who contract the virus and to safeguard the health and well-being of those who are most vulnerable to disease transmission. Dr. Dermot Kelleher

The researchers are hopeful that the treatment could help reduce hospitalizations and one day delay or even eliminate the need for mechanical ventilators for patients who contract the disease. They also see great potential for the therapy to be used as a prophylactic, or preventative treatment, capable of temporarily reducing the risk of infection and protecting healthcare workers on the frontlines as well as others at increased risk.

This is an excellent example of the world-class biomedical research taking place at UBCs Academy of Translational Medicine (ATM), says Dr. Poul Sorensen, director of the ATM. The ATM is a powerful innovation hub dedicated to accelerating the translation of scientific discoveries into clinical practice, rapidly solving some of lifes most pressing health challengesfrom COVID-19 and cancer to diabetes and dementiabringing real and lasting hope to everyone.

This research also nicely complements the groundbreaking work underway in Dr. Josef Penningers laboratory at UBCs Life Sciences Institute (LSI), where they are examining the use of an inhalable form of the ACE2 protein to bind the virus and halt COVID-19, adds Dr. Sorensen.

Within UBCs Life Sciences Institutethe largest biomedical research institute of its kind in Canadathe research team is already hard at work in the Kelleher lab, using cutting-edge technology to identify and design molecules to target SARS-CoV-2, the virus that causes COVID-19.

Once inhaled, these specialized molecules, known as GapmeRs, would stick to the virus and degrade its DNA, thereby preventing the virus from replicating further, while limiting infection and further transmission.

Dr. Shane Duggan

Ultimately, by embracing GapmeR technology and a simple delivery system, such as a nebulizer that doesnt rely on specialized equipment, the researchers believe their approach could represent a much more cost-effective means of combatting COVID-19 and saving lives around the worldincluding harder-to-reach regions.

Its our duty as researchers to use every tool in our toolkit to advance knowledge of COVID-19 and rapidly rethink our current treatment approaches to make a direct impact on patient lives both here in Canada and around the world. Dr. Shane Duggan

Treatments based on GapmeR technology are relatively easy to manufacture and require no specialized storage or transport, which make them ideal for distributing to vulnerable communities in need, says Dr. Duggan, a research associate in the division of gastroenterology.

In the coming months, the research team, which has recently grown to include two postdoctoral fellows with expertise in virology, will begin rapidly identifying molecular candidates with the highest chance of success. Following this, they will begin working with the live virus.

In an effort to accelerate the development of the new treatment, the UBC research team will also collaborate with a group of scientists with expertise in GapmeR technologies led by Dr. Navin Verma at the Lee Kong Chian School of Medicine, Nanyang Technological University in Singapore. Through this international partnership, the team hopes to bolster the studies needed to turn their research into a clinical reality, ultimately expediting the path from bench to bedside.

Beyond COVID-19, the treatment approach has the potential to be rapidly mobilized and tailored to fight future viral outbreaksand could one day be used to help tackle other diseases, including some forms of cancer.

The beauty behind this technology is that it holds tremendous potential because its readily translatable and scalable, says Dr. Duggan.

But right now, with COVID-19 forecasted to remain for the foreseeable future, the research team remains focused on the current pandemic and accelerating an aerosol treatment to save lives.

COVID-19 has already claimed the lives of millions and impacted millions more around the world, says Dr. Duggan, who, after losing a family member to a combination of COVID-19 and liver dysfunction last year, understands the high stakes at hand more than most.

Its our duty as researchers to use every tool in our toolkit to advance knowledge of COVID-19 and rapidly rethink our current treatment approaches to make a direct impact on patient lives both here in Canada and around the world.

At UBC, this is hope, accelerated.

Read the original post:
Halting COVID-19 in its tracks - UBC Faculty of Medicine

Read More...

Namesake of new center a young man in love with the pursuit of knowledge – The Saint Anselm Crier

November 7th, 2021 1:53 am

2004 Saint Anselm alum Greg Grappone had his lifes ambitions and virtues memorialized in the form of a institute for humanities situated behind Alumni Hall.

At age 35, Grappone passed on May 1, 2015 in Seattle after complications from a graft-versus-host disease succeeding a stem cell transplant for a rare form of cancer. Grappone led his life as a father, a husband, and a son, and after graduating he found himself as the owner of his familys car dealership that stretches Route 3A in Bow, New Hampshire. The Grappone company was said to have been built upon a philanthropic reputation which parallelled the way in which Greg Grappone held himself. Grappone held a deep passion regarding cultural, social and political issues. He relished in his own personal pursuit for truth regarding these subjects, and it was because of this that he was seen as an inspiration to all. Grappone, as this type of intellect, spent much of his life grounded by lifes unanswerable questions.

Grappones consistent search to understand the world around him demonstrated a clear path in becoming a Great Books major for the Saint Anselm class of 2004. His adventures saturated in curiosity were accompanied by the stories the Great Books told; to which he viewed them as life companions rather than just educational implements Grappone luxuriated in the wisdom that these books provided and the questions and conversations that they provoked. One of Grappones professors, Father John, depicted the extent of Grappones intellectual curiosity by explaining how [Greg was] very interested in learning and eager to discuss the Great Books we read not only for their content but also for how they could help him be a better person. As a professor, it is always a pleasure to work with a student whose primary focus is learning, not grades. This pursuit of higher intellect was bolstered by Grappones person as a whole, as he was praised for, His great attitude and kindly, gentlemanly manner.

Grappones fascination for the humanities had fostered the foundation for a permanent home for the cultivation of intellect on the Saint Anselm campus. In an article to the Concord Monitor, Gregs parents, Robert and Beverly discussed how they were searching for a meaningful way to honor their sons memory, and it was at this time where Saint Anselm College was in search of enlivening their humanities department. The brevity of Grappones life ended with daily correspondence with his father and American filmmaker Ken Burns. The three would engage in conversation surrounding wisdom laid forth by Russian author and philosopher Leo Tolstoy. Because of the relationship that Grappone and Burns shared, Burns served as the honorary chair of the new humanities building campaign on campus. Grappones parents, in recognition of the importance in further the development of higher education stated, We believe that now more than ever we all need to do what we can to enlighten our minds, feed our souls and lift our spirits and those of others by heeding the instructions of Tolstoy: you have to embrace what the wisdom of humanity, your intellect and your heart tell you: that the meaning of life is to serve the force that sent you into the world. Then life becomes a joy.

Father John, in acknowledging the life lessons that Grappone exemplified as a student, stated that students could take away this lesson: Focus on learning, not on grades! Strive to be a better person today than you were yesterday. It is because based upon this mindset, that Grappone will forever be remembered at the Saint Anselm campus.

Donations can be made to the following causes that were identified as meaningful to the Grappone name, found in the Concord Monitor 2015:

Read the original post:
Namesake of new center a young man in love with the pursuit of knowledge - The Saint Anselm Crier

Read More...

Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries – KULR-TV

November 7th, 2021 1:53 am

Success Story of Extracorporeal Shock Wave Therapy (ESWT)

Successful for over 40 years in urology for the disintegration of kidney stones, with high efficiency and hardly any side effects worth mentioning.

How does the shock wave work?

Without causing mechanical damage, shockwaves trigger a biological response in the treated tissue through their compressive, tensile and shear forces (mechanotransduction). Genes are activated in the cell nucleus starting to produce proteins (including growth factors) responsible for the healing process. This also causes increased ingrowth of newly formed blood vessels, which improves local metabolism. The additional modulation of the inflammation necessary for healing enables regeneration of pathological tissue.

Recent studies prove.

Shockwaves also trigger the production of messenger substances to the cell nucleus, which mobilize the body's own stem cells from the bone marrow, stimulating them to migrate to the treated tissue, settle there and develop into the required tissue (e.g. heart muscle cells). Instead of conventional stem cell transplantation shockwaves make it possible to initiate the body's own regeneration without risk of complications.

Therapy for a wide variety of tissues.

Since the underlying pathology can be treated with these methods, shockwave therapy is being used in more and more medical disciplines.

This creates a tool that opens up completely new possibilities in tissue regeneration without triggering significant side effects. Since conventional medicine has not been able to offer any significant therapeutic options to date, the present results of shockwave therapy are of particular importance and are therefore applied in the following areas. It can be assumed that shockwave therapy can be used in practically all medical specialties.

Spinal cord injury/cross-sectional lesion.

What was long considered unthinkable is now one of the major hopes for causal therapy: shockwave has also made great progress in the treatment of paraplegia. Since November 2020, the first patients have been included in an Austria-wide study. Due to the COVID pandemic, the initiation of the individual study centers has been somewhat delayed, but so far eight patients have already been enrolled in the study. In addition, the Unfallkrankenhaus Berlin, one of the most important centers for spinal cord injury in Germany, will participate in the study.

Dr. Wolfgang Schaden, adj. Prof., President of ISMST, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Deputy Medical Director of AUVA, Austria

Cardiac Surgery.

Regeneration of heart muscle after myocardial infarction has long remained a dream of modern medicine. Despite extensive efforts to develop stem cell and gene therapies, none of these methods could be brought into clinical routine. Cardiac shockwave therapy brings a scientific breakthrough: Cardiac function is improved, and impressive results show the increase of patients' quality of life. Shockwave therapy in cardiac surgery has a favorable side effect profile and is on the verge of bringing cardiac regeneration into daily clinical practice.

PD Dr. Johannes Holfeld, University Department of Cardiac Surgery, Innsbruck Medical University, Austria.

Sexual Medicine.

Low-energy shockwave therapy has been a fabulous addition to sexual medicine armamentarium for men and women with various forms of sexual dysfunction, e.g. erectile dysfunction, premature ejaculation, persistent genital arousal disorder PGAD/genito-pelvic dysesthesia GPD. Many patients (and their partners) describe these comfortable and quick shockwave treatments as life changing.

Prof. Dr. Irwin Goldstein, Alvarado Hospital, San Diego, CA, USA

Aesthetic-, hand-, burn- and reconstructive surgery.

Shockwave medicine can support these four pillars of surgery noninvasively. Two significant examples: In aesthetic surgery with significant improvement in cellulite with shockwave therapy after six to eight sessions, lasting for a period of about one year. In burns, shockwave therapy can accelerate epithelialization (healing) of superficial burn injuries clinically relevant by three days, with a significant reduction in infections and hospitalization.

Prof. Dr. Karsten Knobloch, SportPraxis Prof. Knobloch, Hanover, Secretary General of the German Shockwave Society DIGEST.

Sports Medicine.

After more than 30 years of experience, shock wave treatment is now a standard in sports medicine and rehabilitation facilities worldwide.

Leprosy.

Shockwaves used in a similar way as for diabetic foot ulcers have also led to the healing of wounds in leprosy patients and significantly improved the quality of life of these patients. This work, carried out in Agua de Dios, Colombia, by the Bosque University group in Bogot, is now being used in several medical centers around the world with very positive results.

Prof. Dr. Carlos Leal, Bosque University, Fenway Medical, Bogot, Colombia.

Wound healing.

Chronic wounds are challenging for patients concerned and practitioners and will have an increasing impact on health care systems. Treatment with shockwaves has a positive conditioning influence on the wounds and in a high proportion for healing, independent of otherwise aggravating factors (e.g. diabetes mellitus, immunosuppression, cortisone therapy, and other exacerbating factors).

With an average treatment frequency of one treatment every second week, in addition to the established wound therapy, healing was observed in more than 70% of the cases of ulcers and other wound healing disorders.The therapy is free of side effects and helps to reduce the burden of the health care system due to the enormous savings potential.

Rainer Mittermayr, MD, MBA, assoc. Prof., Treasurer of the ISMST and Conference Secretary, Senior Surgeon Orthopedic and Traumatology, AUVA (Austrian Workers Compensation Board, Vienna, Austria)

Originally posted here:
Shockwave therapy brings new healing opportunities for heart attack patients and hope for people with spinal cord injuries - KULR-TV

Read More...

Page 190«..1020..189190191192..200210..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick